| Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001–2009 IV Kuzmin, M Shi, LA Orciari, PA Yager, A Velasco-Villa, NA Kuzmina, ... PLoS pathogens 8 (6), e1002786, 2012 | 208 | 2012 |
| Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection AI Flyak, X Shen, CD Murin, HL Turner, JA David, ML Fusco, R Lampley, ... Cell 164 (3), 392-405, 2016 | 183 | 2016 |
| SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study AG Letizia, Y Ge, S Vangeti, C Goforth, DL Weir, NA Kuzmina, ... The Lancet Respiratory Medicine 9 (7), 712-720, 2021 | 179 | 2021 |
| Raccoon rabies virus variant transmission through solid organ transplantation NM Vora, SV Basavaraju, KA Feldman, CD Paddock, L Orciari, ... Jama 310 (4), 2013 | 123* | 2013 |
| Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors NA Kuzmina, P Younan, P Gilchuk, RI Santos, AI Flyak, PA Ilinykh, ... Cell reports 24 (7), 1802-1815. e5, 2018 | 96 | 2018 |
| Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization P Gilchuk, CD Murin, JC Milligan, RW Cross, CE Mire, PA Ilinykh, ... Immunity 52 (2), 388-403. e12, 2020 | 93 | 2020 |
| Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein P Gilchuk, N Kuzmina, PA Ilinykh, K Huang, BM Gunn, A Bryan, ... Immunity 49 (2), 363-374. e10, 2018 | 85 | 2018 |
| Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region AI Flyak, N Kuzmina, CD Murin, C Bryan, E Davidson, P Gilchuk, ... Nature microbiology 3 (6), 670-677, 2018 | 81 | 2018 |
| Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein NA Kuzmina, IV Kuzmin, JA Ellison, CE Rupprecht J Antivir Antiretrovir 5 (2), 37-43, 2013 | 64 | 2013 |
| Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies PA Ilinykh, K Huang, RI Santos, P Gilchuk, BM Gunn, MM Karim, J Liang, ... Cell host & microbe 27 (6), 976-991. e11, 2020 | 58 | 2020 |
| COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models P Maisonnasse, Y Aldon, A Marc, R Marlin, N Dereuddre-Bosquet, ... Nature communications 12 (1), 6097, 2021 | 50 | 2021 |
| Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2 DF Lake, AJ Roeder, E Kaleta, P Jasbi, K Pfeffer, C Koelbela, ... Journal of Clinical Virology 145, 105024, 2021 | 47 | 2021 |
| Phylogenetic and epidemiologic evidence of multiyear incubation in human rabies TA Boland, D McGuone, J Jindal, M Rocha, M Cumming, CE Rupprecht, ... Annals of neurology 75 (1), 155-160, 2014 | 46 | 2014 |
| The phylogeography and spatiotemporal spread of south-central skunk rabies virus NA Kuzmina, P Lemey, IV Kuzmin, BC Mayes, JA Ellison, LA Orciari, ... PloS one 8 (12), e82348, 2013 | 46 | 2013 |
| Chimeric filoviruses for identification and characterization of monoclonal antibodies PA Ilinykh, X Shen, AI Flyak, N Kuzmina, TG Ksiazek, JE Crowe Jr, ... Journal of virology 90 (8), 3890-3901, 2016 | 45 | 2016 |
| A reassessment of the evolutionary timescale of bat rabies viruses based upon glycoprotein gene sequences NA Kuzmina, IV Kuzmin, JA Ellison, ST Taylor, DL Bergman, B Dew, ... Virus Genes 47, 305-310, 2013 | 44 | 2013 |
| Dissecting strategies to tune the therapeutic potential of SARS-CoV-2–specific monoclonal antibody CR3022 C Atyeo, MD Slein, S Fischinger, J Burke, A Schäfer, SR Leist, ... JCI insight 6 (1), 2021 | 37 | 2021 |
| Asymptomatic SARS-CoV-2 infection is associated with higher levels of serum IL-17C, matrix metalloproteinase 10 and fibroblast growth factors than mild symptomatic COVID-19 A Soares-Schanoski, N Sauerwald, CW Goforth, S Periasamy, DL Weir, ... Frontiers in Immunology 13, 821730, 2022 | 36 | 2022 |
| Pan-ebolavirus protective therapy by two multifunctional human antibodies P Gilchuk, CD Murin, RW Cross, PA Ilinykh, K Huang, N Kuzmina, ... Cell 184 (22), 5593-5607. e18, 2021 | 32 | 2021 |
| Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects M Meyer, BM Gunn, DC Malherbe, K Gangavarapu, A Yoshida, ... Science translational medicine 13 (602), eabg6128, 2021 | 32 | 2021 |
Alexander BukreyevThe University of Texas Medical Branch at Galveston, Galveston National LaboratoryVerified email at utmb.edu